New drug BIIB142 tested in humans for the first time
NCT ID NCT07133828
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing the safety of a new drug called BIIB142 in 78 healthy adults. Participants receive either the drug or a placebo, in single or multiple doses, to see how the body handles it and whether it causes any side effects. The study is split into two parts: Part A tests a single dose, and Part B tests daily doses for 14 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIIB142
What could go wrong
This is an early phase 1 trial in healthy volunteers, so it only tests safety and how the drug moves through the body. There is no disease being treated, so success here does not guarantee any future treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PPD Development, LP
RECRUITINGLas Vegas, Nevada, 89113, United States
Contact Phone: •••-•••-••••
Contact